

## Altreno<sup>™</sup> (tretinoin) – New drug approval

- On August 23, 2018, the FDA approved Ortho Dermatologics Altreno (tretinoin) 0.05% lotion for the topical treatment of acne vulgaris in patients 9 years of age and older.
  - Altreno is the first lotion formulation of tretinoin.
- Acne is a skin condition that occurs when hair follicles become plugged with oil and skin cells. This
  often causes whiteheads, blackheads or pimples and appearing on the face, forehead, chest, upper
  back and shoulders. Acne is most common among people ages 12 to 24, though it can affect people of
  all ages. Depending on its severity, acne can cause emotional distress and scar the skin.
- The American Academy of Dermatology states that acne is the most common skin problem in the United States affecting up to 50 million Americans. Acne can occur at any stage of life and may continue into one's 30s and 40s. Acne occurring in adults is increasing, affecting up to 15% of women.
- Tretinoin is a metabolite of vitamin A that binds with high affinity to specific retinoic acid receptors
  located in both the cytosol and nucleus. Tretinoin activates three members of the retinoic acid nuclear
  receptors which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth
  and differentiation.
- The safety and efficacy of Altreno was evaluated in two vehicle controlled phase 3 studies enrolling 1,640 patients.
  - At week 12, 16.5% and 19.8% of patients in trials 1 and 2, respectively, achieved improvements in acne symptoms with tretinoin 0.05% lotion, compared to only 6.9% and 12.5% with vehicle.
  - Patients treated with Altreno saw a mean absolute reduction of 17.8 and 21.9 in non-inflammatory lesions in trials 1 and 2, compared to 10.6 and 13.9 in patients treated with vehicle.
  - Patients treated with Altreno saw a mean absolute reduction of 13.1 and 13.9 in inflammatory lesions in trials 1 and 2, compared to 10.6 and 10.7 in patients treated with vehicle.
- Warnings and precautions of Altreno include skin irritation, fish allergies, ultraviolet light and environmental exposure.
- The most common adverse reactions (≥ 1% and greater than vehicle) with Altreno use were dryness, pain, erythema, irritation and exfoliation (all at the application site).
- The recommended dose of Altreno is to apply a thin layer to affected areas once daily. Avoid eyes, mouth, paranasal creases, and mucous membranes.
- Valeant Pharmaceuticals plans to launch Altreno by the 4<sup>th</sup> quarter of 2018. Altreno will be available
  as a tretinoin 0.05% lotion.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.